Moberg Pharma and Karo Healthcare Expand Collaboration into China's Cross-Border E-commerce Market
Moberg Pharma and Karo Healthcare have signed an agreement to introduce the antifungal medication MOB-015 (Terclara) into the Chinese market through cross-border e-commerce channels, a key step in their global expansion strategy.
What are the key facts?
- 1Channel: Cross-border e-commerce (CBEC)
- 2Product: Antifungal medication MOB-015
- 3Strategy: Quick entry via cross-border channels, with future consideration for general trade
What happened?
Moberg Pharma and Karo Healthcare have signed a licensing agreement to bring the antifungal medication MOB-015 (Terclara) to China. The two parties have opted for an initial launch through the rapidly growing cross-border e-commerce channels, aiming for quick market entry while accumulating data and experience for future general trade market entry.
What does this mean for cross-border sellers?
Cross-border e-commerce has become the preferred low-cost channel for pharmaceutical and health brands to test demand in the Chinese market and achieve rapid startup.